nach Quartalsbericht mit deutlich reduziertem Verlust und mehreren Kaufempfehlungen Kursziel 17$,Stochstik bereits relativ hoch Alert: UBS Warburg reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:49 PM EDT ? Alert: First Union Sec reiterates coverage of ORCH at Strong Buy (Headline only) Briefing.com - 12:42 PM EDT ? Alert: Robertson Stephens reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:32 PM EDT
Orchid BioSciences, Inc. (Nasdaq: ORCH) Previous Close: Up 16% to $4.75 on vol. 2,167,400 Shares: ACCUMULATE
Orchid BioSciences, Inc. (Nasdaq: ORCH) announced that it has successfully performed ultra-high throughput genotyping using its proprietary SNP-IT(TM) SNP scoring technology on two different instrument platforms. Orchid is the first company to demonstrate the feasibility of ultra-high throughput SNP scoring on multiple platforms. Both systems serve as scalable components of Orchid's MegaSNPatron(TM) facilities that provide SNP scoring services primarily for high volume users like pharmaceutical and agricultural companies.
Orchid BioSciences recently reported financial results for its first quarter ended March 31, 2001. Total revenues for the first quarter of 2001 increased to $5.6 million, up from $3.5 million for the same period in 2000, an increase of 60 percent. The increase in revenues during the first quarter resulted primarily from placements of SNPstream(R) 25K platforms, sales of SNPware(TM) consumable kits, sales of single nucleotide polymorphism (SNP) scoring and DNA and other genetic diversity testing services, collaboration and license fees, and the addition of Cellmark Diagnostics, which Orchid acquired in February, 2001.
Orchid BioSciences, Inc. is a leading provider of products, services and technologies for SNP scoring and genetic diversity analyses. Orchid has developed SNP-IT, its proprietary SNP analysis technology and markets SNPstream instruments and SNPware(TM) consumables that rapidly generate highly accurate, cost effective SNP information. SNP-IT is usable in environments ranging from small-scale laboratories to large commercial facilities. Its versatility also has enabled Orchid to partner with industry leaders to make SNP-IT-enabled products available on a wide variety of instrument platforms.
Allerdings neues SECFiling über geplante Kapitalerhöhung!
Aastrom Biosciences, Inc. (Nasdaq: ASTM) auf die Watchlist,Recherche bei www.quicken.com oder www.clearstation.com möglich,gerade wieder unt 1$ gefallen,sind in der Krebsforschung tätig ,stoppen Tumorwachstum in Versuchsphase II(?)
Boston, May 15, 2001 (Midnight Trader via COMTEX) -- Aastrom Biosciences (ASTM) reported this morning it received a patent for its process for growing and harvesting human cells ex vivo in a cassette chamber format, without exposing the cells to the environment. The stock is rising this morning on 4,500 Island shares.
schon gestern und heute.Am 16.5. 1,05 heute 2,41 bei rasantem Volumen von 2,9 Millionen,Stochastik allerdings weit oben .Sollte sicher auf die Watchlist.Wie auch Orchid !
ANN ARBOR, Mich. (Dow Jones)--Aastrom Biosciences Inc. (ASTM, news, msgs) and Neoprobe Corp. (NEOP, news, msgs) are collaborating to develop a new immune system cell therapy product to treat cancer. In a press release Tuesday, the companies said they will use Aastrom's AastromReplicell system and lymphocyte production technologies to produce a therapeutically active product based on Neoprobe's lymph node lymphocyte cell therapy. Neoprobe said breast and colorectal cancer patients treated with its LNL cell therapy had an extended median survival and an improved response to standard chemotherapy. Company Web site: http://www.neoprobe.com Aastrom develops automated cell therapy technology and devices for cancer patients who have undergone chemotherapy or radiation treatment.